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Promoting ethical standards in globalized drug 
trials through market exclusion 
By Fazal Khan, Assistant Professor of Law, UGA
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She was only ten years old and 
suffering from a serious infectious disease 
that was sweeping through West Africa, 
bacterial meningitis. But for this little girl 
and her family there was seemingly good 
news; there exists an effective treatment 
for bacterial meningitis, intravenous 
antibiotics. Further, once they arrived 
at the clinic in Kano, Nigeria, they saw 
Western doctors in white coats offering to 
provide medical treatment for free. And 
yet, three days later the girl died – not 
having received any proven antibiotic 
therapy, but only an experimental drug 
called Trovan.1 
The family of the girl later claimed, 
along with many others, that instead of 
receiving proper medical care, they were 
unwitting participants in a multinational 
drug company’s experimental trial that 
led to the death or serious impairment 
of numerous children.2  But why would a 
drug company ever do something like this? 
Well, if data from the experiment helped 
the drug obtain market approval, and it 
became a market blockbuster, a company 
would have over a billion reasons. 
The potential for tremendous financial 
reward generated by a newly approved 
drug provides a strong incentive for drug 
companies to move human subject testing 
to “developing countries,” where minimal 
ethical guidelines and little transparency 
are the norm. The drug industry is acutely 
aware that there is minimal threat of costly 
civil and criminal legal sanctions for any 
of their ethical violations in impoverished 
countries. One study looking at drug trials 
in sub-Saharan Africa found that only 16 
percent of these clinical drug trials met 
international ethical standards, despite 81 
percent of them reporting oversight by an 
ethics review board. 3 
The globalization of clinical trials really 
became enabled after a 1980 Food and 
Drug Administration (FDA) ruling that 
allowed data from foreign trials to be 
used in new drug applications (NDA). 
Certain foreign studies used 
to support an NDA may opt to 
avoid direct FDA regulation, but 
must still satisfy FDA-imposed 
ethical standards – either 
the Declaration of Helsinki 
guidelines or regulations of the 
country where the research 
was conducted, “whichever 
represents the greater 
protection of the individual.”4 
The Declaration of Helsinki, 
an ethical code put out by the 
World Medical Association that governs 
research involving human subjects, has 
thus become the de facto international 
ethical standard. Therefore, in theory, 
under these FDA guidelines there should 
not be a “race to the bottom” problem, 
as an underdeveloped country’s lax 
standards would automatically be 
upgraded to Declaration of Helsinki 
standards. And yet, we are still seeing 
consistent violations of ethical standards. 
Globalization of the pharmaceutical 
industry and clinical drug testing is 
not necessarily a bad thing. Indeed, 
without this process, cures for seemingly 
intractable diseases like cancer or AIDS 
might not be possible in the near future. 
Further, many patients in the developing 
world might not have access to any 
medical attention at all, were it not for 
clinical drug testing. However, the real and 
potential benefits offered by globalization 
in the drug industry do not require us 
to silently accept violations of ethical 
standards or the absence of accountability 
and justice. As Nobel-laureate economist 
Amartya Sen has stated: 
Even though I’m pro-globalization, 
I have to say thank God for the anti-
globalization movement. They’re putting 
important issues on the 
agenda… My attitude to 
globalization is that one 
has to recognize first of all 
its inevitability, secondly its 
importance as an intellectual, 
social, political force, even 
as an economic force, but 
recognize that it can be very 
unjust and unfair and unequal, 
but these are matters under 
our control.5 
In other words, even though 
the process may be inevitable, we are 
not powerless to control the actions of 
drug companies who conduct testing on 
human subjects in developing nations. 
What can be done to address this 
problem? Multinational companies are 
notoriously difficult to regulate. By using 
multiple facilities around the globe, 
corporations can strategically evade state 
power and certain national regulatory 
schemes. From an international law 
perspective, the challenges are both 
“horizontal” and “vertical” in nature, and 
the legal responses can be “hard” or “soft.” 
For clinical drug trials, “horizontal” 
challenges constitute problems that 
arise between nations trying to regulate 
multinational drug companies that 
operate across international borders. 
“Vertical” challenges are problems with 
unethical trials that nations, more likely 
developing nations with limited resources, 
face inside their borders. “Hard-law” is 
represented by rule-based systems with 
binding authority on member states, 
1 Joe Stephens, The Body Hunters: Exporting Human Experiments: Where Profits and Lives Hang in the Balance: Finding an Abundance of Subjects and Lack of Oversight Abroad, Big Drug 
Companies Test Offshore to Speed Products to Market, WASH. POST., Dec. 17, 2000, at A1.
2 Abdullahi v. Pfizer, 2002 U.S. Dist. LEXIS 17436.
3 See David M. Kent et al., Clinical Trials in Sub-Saharan Africa and Established Standards of Care: Systematic Review of HIV, Tubercolosis, and Malaria Trials, 292 JAMA 237, 239 (2004).
4 See 21 C.F.R. Sec. 312.120(5)(c)(1)(2005).
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such as the system in place under the 
World Trade Organization (WTO). “Soft-
law” represents guidelines, practices, and 
policies generated by non-governmental 
organizations for voluntary self-regulation 
by industry or future adoption by states. 
Addressing the ethical problems 
associated with globalized trials, some 
scholars have advocated a “hard, 
horizontal” approach, investing an 
international organization such as the 
World Health Organization (WHO) with 
binding authority to enforce ethical 
standards in clinical trials on a global basis. 
The problem with this approach is one of 
sovereignty and enforcement. Namely, 
how would an international organization 
enforce its decisions upon an unwilling 
sovereign nation? 
Other commentators have argued for a 
“hard, vertical” approach with horizontal 
effects; that is, an expansive reading of 
the Alien Tort Statute (ATS) to allow U.S. 
courts to enforce foreign violations of 
ethical standards. However, after the U.S. 
Supreme Court’s 2004 decision in Sosa v. 
Alvarez-Machain, it became more difficult 
for foreign plaintiffs to assert ATS claims. 
Indeed, the class of Nigerian plaintiffs who 
sued Pfizer in the U.S. over their Trovan 
drug trials (see supra) had their case 
dismissed for failure to state a cognizable 
ATS claim (the court indicated that their 
suit would be dismissed on forum non 
conveniens grounds as well). Thus, while 
the proposals discussed above advocate 
for more accountability and justice in 
globalized drug trials, it is unlikely that in 
practice they would offer more protection 
for vulnerable research populations. 
A more feasible and effective strategy 
would be to use “horizontal, soft-law” 
measures such as increased monitoring 
and reporting on globalized drug trials 
that in turn could be used to enforce 
existing “hard-law” drug approval 
regulations vertically in lucrative markets 
such as the United States, Japan, and 
the European Union. The significance of 
these provisions is that drugs developed 
unethically could technically be excluded 
from the marketplace because of the 
impermissibility of the underlying clinical 
trials. Thus, if the fruits of unethical 
research were denied access to U.S., 
Japanese, or EU markets, it would have 
the same effect as a global prohibition, as 
no drug company would develop a drug 
in such a manner if they knew they would 
lose out on even one of these lucrative 
markets. 
With the increasing accessibility of 
cheap internet communication, human 
research subjects and concerned citizens 
in developing nations can be empowered 
to effectuate much of the surveillance and 
monitoring activities of clinical drug trials. 
For instance, WHO could maintain a multi-
lingual website for the reporting of alleged 
ethical violations. A credible report could 
then prompt WHO officials to obtain a 
sworn statement from the reporter, which 
would then trigger an investigation into 
the alleged ethical abuses. Verified reports 
of ethical abuses can then be taken into 
account by drug regulatory agencies when 
determining whether a drug should obtain 
market approval. 
…The potential for tremendous financial reward generated by a 
newly approved drug provides a strong incentive for drug companies 
to move human subject testing to “developing countries,” where 
minimal ethical guidelines and little transparency are the norm. 
“
”
